New cancer immunotherapy could teach the immune system to target tumors
Cancer treatment is increasingly moving away from traditional chemotherapy and toward therapies that train the body’s own immune system to fight disease. New early-stage clinical trial results from biotech company ExpreS2ion suggest that this approach may continue to expand in the coming years.
The company has reported early data from a Phase I clinical trial of a new immunotherapy designed to target HER2-positive cancers, including certain types of breast cancer. The treatment works by stimulating the immune system to produce antibodies that recognize and attack cancer cells.
A different approach to cancer treatment
Many modern cancer treatments focus on directly attacking cancer cells using drugs, radiation, or engineered antibodies. This new approach instead aims to train the immune system to recognize cancer cells on its own and continue fighting them over time.
The therapy targets a protein called HER2, which is overexpressed in some breast cancers and other tumor types. According to the company’s early clinical data, most patients in the study developed antibodies targeting HER2 after receiving the treatment, and those antibody levels increased over time with repeated doses.
If successful in later trials, this type of treatment could potentially provide longer-lasting protection by teaching the immune system to recognize cancer cells and respond to them in the future.
Immunotherapy becoming a major area of innovation
Immunotherapy is already one of the fastest-growing areas in medicine and biotechnology. Treatments such as checkpoint inhibitors and CAR-T cell therapy have already transformed treatment for certain cancers over the past decade.
Researchers are now exploring vaccines and virus-like particle technologies that train the immune system to recognize cancer in a similar way to how vaccines train the immune system to recognize viruses.
This approach could potentially:
- Provide longer-lasting protection
- Reduce the need for repeated drug treatments
- Work alongside existing cancer therapies
- Improve survival rates for certain cancers
- Reduce side effects compared to chemotherapy
Early results but long road ahead
The trial results are still early and based on a small number of patients, and the company has emphasized that no conclusions about clinical benefit can yet be made. However, the early data showing immune responses and acceptable safety profiles means the trial will now move forward with higher doses and more patients.
If future trials are successful, treatments like this could become part of a new generation of cancer therapies that focus on immune system training rather than direct tumor destruction.
The future of cancer treatment may look like vaccination
One of the most interesting long-term implications of this type of research is the possibility that some cancers could eventually be treated more like chronic diseases — or even prevented — through immune system training.
Researchers around the world are working on cancer vaccines, personalized immunotherapy, and immune system engineering. While many of these technologies are still in clinical trials, they represent one of the biggest technological shifts in medicine.
Instead of simply treating cancer after it appears, future treatments may increasingly focus on teaching the immune system to detect and stop cancer cells before they grow into dangerous tumors.